Self-Paced Online Course

7 hours of learning
Self-paced, on-demand modules.

Course Access

90-day access
Structured learning following enrollment.

The Use of Cell Therapies for Autoimmune Diseases: CAR-T

Dive into the forefront of CAR-T therapy for autoimmune diseases in this 7-hour on-demand course. Designed for clinicians, researchers, and industry leaders, it covers the full spectrum from basic research to clinical practice.

Learn from pioneering experts as they share advanced insights into CAR-T development, explore targeted biological therapies, and discuss solutions to key clinical challenges. The course also addresses regulatory requirements, manufacturing processes, and practical strategies for translating CAR-T therapies from bench to bedside.

Through real-world case studies, clinical success stories, and the latest data, registries, and reports, you’ll gain a comprehensive understanding of the clinical applications of CAR-T therapies for autoimmune diseases.

Based on Past Participant Survey Results

93%

Said the course content was relevant

92%

Were satisfied with the overall course

94%

Rated the speakers as knowledgeable and clear

Rates (USD)

Training Course Only	ISCT Members	Non-Members
Students / Residents / Postdocs / Fellows	$150	$600
Technologist / Pharmacist / Nurse Practitioner / Nurse	$175
Academia	$200
Start Up	$280
Industry	$350
Tier 1 and Tier 2 Reduced Rate¹	$140
15% Group Registration Discount available for 5+ Members / Non-Members from the same institution.

Group Registration Discount

Receive 15% off when registering 5+ ISCT Members / Non-Members from the same company or institution.

Contact ISCT: workforcedevelopment@isctglobal.org

¹ Tier 1 and Tier 2 Reduced Rate:
Eligible countries listed here.
Reduced rates apply only to Academic / Government / Non-Profit / Technologist / Pharmacist / Nurse categories.

Contact ISCT at workforcedevelopment@isctglobal.org to obtain the reduced rate.

Evolution of CAR-T therapy: from oncology to autoimmune disease applications
B-cell biology, autoimmunity, and targeted biological therapies
Clinical implementation of CAR-T in lupus, rheumatoid arthritis, myositis, multiple sclerosis, and scleroderma
Immune monitoring, CAR-T expansion and persistence, and immune reconstitution
Lymphodepletion strategies, patient selection, and multidisciplinary care models
Statistical design considerations and outcome assessment in autoimmune CAR-T trials
Safety of gene-modified immune cells and risk of secondary malignancies
European regulatory framework (EMA), hospital exemption pathway, and real-world registry data

Rates (USD)

Training Course Only	ISCT Members	Non-Members
Students / Residents / Postdocs / Fellows	$150	$600
Technologist / Pharmacist / Nurse Practitioner / Nurse	$175
Academia	$200
Start Up	$280
Industry	$350
15% Group Registration Discount available for 5+ Members / Non-Members from the same institution

Group Registration Discount:

Receive 15% off when registering 5+ ISCT Members / Non-Members from the same company / institution.
Contact ISCT at workforcedevelopment@isctglobal.org to obtain the discounted Group Registration Rate.

Designed For

Clinical researchers, clinicians, and physicians involved in CAR-T cell translation for clinical applications.

ELIGIBILITY REQUIREMENTS

None

Expert insights on the latest advances and future potential of CAR-T cell therapy for autoimmune diseases
Fundamentals of clinical trial design and key outcomes from CAR-T studies in autoimmune conditions
How to translate research findings into clinical CAR-T cell manufacturing
Building robust evidence to guide clinical decisions and support regulatory submissions

UPON COMPLETION, YOU WILL RECEIVE:

7 CMLE Credits
Certificate of Completion from ISCT

Note: Completing all training modules and passing the quizzes is mandatory to receive a course completion certificate.

ACCREDITED BY:

7 Hours of CMLE Credits

The course offers 7 Hours of CMLE Credits

What Past Participants Are Saying

“It was a very practical course that provided valuable insights for those performing or planning CAR-T cell treatment in immune diseases, covering everything from the laboratory bench to clinical practice.”

Diego Clé

“The whole course was really interesting, very interactive, fun, and inspiring throughout.”

Iskra Pusic

“The whole meeting was excellent, well structured, and very educational. The discussion rounds at the end of each session were a great idea.”

Laura Belver

PLANNING FACULTY

Dominique Farge, MD, PhD

ISCT Regional Vice-President,
Europe Internal Medicine,
St. Louis Hospital
Paris-Cité University

France

Fermin Sanchez-Guijo, MD, PhD

ISCT Immediate Past Regional
Vice-President, Europe
University of Salamanca,
Department of Hematology
University Hospital Salamanca

Spain

Bruce Levine, PhD

ISCT Past President
Barbara and Edward Netter Professor,
University of Pennsylvania

United States

Andreas Mackensen, MD

Deputy Director,
CCC Erlangen-EMN
Director of Medical Clinic 5
(Hematology and Internal Oncology)
University Hospital Erlangen

Germany

Rafaella Greco, MD

EBMT Secretary and Immediate Past Chair
Autoimmune Diseases Working Party
Senior Hematologist
Hematology & Bone Marrow Transplantation
IRCCS San Raffaele Hospital

Spain

Georg Schett, MD, PhD

Vice President of Research &
Department Head
Internal Medicine
University of Erlangen-Nuremberg

Germany

The Use of Cell Therapies for Autoimmune Diseases: CAR-T

The Use of Cell Therapies for Autoimmune Diseases: CAR-T

PLANNING FACULTY

Questions?